JP2008546639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008546639A5 JP2008546639A5 JP2008510301A JP2008510301A JP2008546639A5 JP 2008546639 A5 JP2008546639 A5 JP 2008546639A5 JP 2008510301 A JP2008510301 A JP 2008510301A JP 2008510301 A JP2008510301 A JP 2008510301A JP 2008546639 A5 JP2008546639 A5 JP 2008546639A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- aryl
- alkyl
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 26
- 125000001072 heteroaryl group Chemical group 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 208000004296 neuralgia Diseases 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 12
- -1 cycloheteroalkyl Chemical group 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 11
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 6
- 206010029240 Neuritis Diseases 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 4
- 150000001540 azides Chemical class 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 230000007794 irritation Effects 0.000 claims 4
- 230000000155 isotopic effect Effects 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 206010043269 Tension headache Diseases 0.000 claims 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000001953 sensory effect Effects 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000004371 toothache Diseases 0.000 claims 2
- CJSLXKZWAVSNSS-UHFFFAOYSA-N 3-chloro-7-cyclohexyl-1-(cyclohexylamino)-6,8-dihydro-5h-2,7-naphthyridine-4-carbonitrile Chemical compound C=12CN(C3CCCCC3)CCC2=C(C#N)C(Cl)=NC=1NC1CCCCC1 CJSLXKZWAVSNSS-UHFFFAOYSA-N 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- CEKMYRMUKLEDAM-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-(2-phenylethyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCCC=3C=CC=CC=3)N=CN=C2CC1 CEKMYRMUKLEDAM-UHFFFAOYSA-N 0.000 claims 1
- MCKATWNAHWWXNX-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-[2-[3-(trifluoromethyl)phenyl]ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCCC=3C=C(C=CC=3)C(F)(F)F)N=CN=C2CC1 MCKATWNAHWWXNX-UHFFFAOYSA-N 0.000 claims 1
- QCPWBRUFKOYOBO-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-[[2-(trifluoromethoxy)phenyl]methyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical class N1=CC(C)=CC=C1N1CC2=C(NCC=3C(=CC=CC=3)OC(F)(F)F)N=CN=C2CC1 QCPWBRUFKOYOBO-UHFFFAOYSA-N 0.000 claims 1
- FMCWYPCITGBOLX-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-[[4-(trifluoromethyl)phenyl]methyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical class N1=CC(C)=CC=C1N1CC2=C(NCC=3C=CC(=CC=3)C(F)(F)F)N=CN=C2CC1 FMCWYPCITGBOLX-UHFFFAOYSA-N 0.000 claims 1
- ZZRLTCJZOJCIHC-UHFFFAOYSA-N 7-cyclohexyl-1-(cyclohexylamino)-3-morpholin-4-yl-6,8-dihydro-5h-2,7-naphthyridine-4-carbonitrile Chemical group N1=C(N2CCOCC2)C(C#N)=C2CCN(C3CCCCC3)CC2=C1NC1CCCCC1 ZZRLTCJZOJCIHC-UHFFFAOYSA-N 0.000 claims 1
- MBPDMPQGMKKBDF-UHFFFAOYSA-N 7-cyclohexyl-1-(cyclohexylamino)-3-piperidin-1-yl-6,8-dihydro-5h-2,7-naphthyridine-4-carbonitrile Chemical compound N1=C(N2CCCCC2)C(C#N)=C2CCN(C3CCCCC3)CC2=C1NC1CCCCC1 MBPDMPQGMKKBDF-UHFFFAOYSA-N 0.000 claims 1
- 235000003934 Abelmoschus esculentus Nutrition 0.000 claims 1
- 240000004507 Abelmoschus esculentus Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003399 Arthropod bite Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010069632 Bladder dysfunction Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010006784 Burning sensation Diseases 0.000 claims 1
- 208000001387 Causalgia Diseases 0.000 claims 1
- 206010008334 Cervicobrachial syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000034347 Faecal incontinence Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 206010049949 Intercostal neuralgia Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000002472 Morton Neuroma Diseases 0.000 claims 1
- 208000020059 Morton neuralgia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010068106 Occipital neuralgia Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000004078 Snake Bites Diseases 0.000 claims 1
- 208000003589 Spider Bites Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- 201000007637 bowel dysfunction Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 229960002504 capsaicin Drugs 0.000 claims 1
- 235000017663 capsaicin Nutrition 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 208000037805 labour Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- OBPXACGGOMKVLV-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCC=3C=C4OCOC4=CC=3)N=CN=C2CC1 OBPXACGGOMKVLV-UHFFFAOYSA-N 0.000 claims 1
- DXGORADRDISYAD-UHFFFAOYSA-N n-(cyclohexylmethyl)-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCC3CCCCC3)N=CN=C2CC1 DXGORADRDISYAD-UHFFFAOYSA-N 0.000 claims 1
- VOICQPYJFZIJSN-UHFFFAOYSA-N n-[(2,3-difluorophenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical class N1=CC(C)=CC=C1N1CC2=C(NCC=3C(=C(F)C=CC=3)F)N=CN=C2CC1 VOICQPYJFZIJSN-UHFFFAOYSA-N 0.000 claims 1
- WFTRPAANKZLHNU-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCC=3C(=CC=CC=3)Cl)N=CN=C2CC1 WFTRPAANKZLHNU-UHFFFAOYSA-N 0.000 claims 1
- FIXOWTFOEIUTMF-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC=C1CNC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 FIXOWTFOEIUTMF-UHFFFAOYSA-N 0.000 claims 1
- NPSGDTBYKGZOCT-UHFFFAOYSA-N n-[(2-methylphenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCC=3C(=CC=CC=3)C)N=CN=C2CC1 NPSGDTBYKGZOCT-UHFFFAOYSA-N 0.000 claims 1
- ZFFRYTRFMCOESZ-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCC=3C=C(Cl)C=CC=3)N=CN=C2CC1 ZFFRYTRFMCOESZ-UHFFFAOYSA-N 0.000 claims 1
- JOFHBLXBUDVYEL-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCC=3C=C(F)C=CC=3)N=CN=C2CC1 JOFHBLXBUDVYEL-UHFFFAOYSA-N 0.000 claims 1
- VRHHZTYCWGFIIU-UHFFFAOYSA-N n-[(3-methoxyphenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(CNC=2C=3CN(CCC=3N=CN=2)C=2N=CC(C)=CC=2)=C1 VRHHZTYCWGFIIU-UHFFFAOYSA-N 0.000 claims 1
- DLHPMQWXJJUYJE-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCC=3C=CC(Cl)=CC=3)N=CN=C2CC1 DLHPMQWXJJUYJE-UHFFFAOYSA-N 0.000 claims 1
- NALREZXCDIQRQU-UHFFFAOYSA-N n-[(4-fluoro-3-methylphenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCC=3C=C(C)C(F)=CC=3)N=CN=C2CC1 NALREZXCDIQRQU-UHFFFAOYSA-N 0.000 claims 1
- CGMKVHOIAYZASS-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1CNC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 CGMKVHOIAYZASS-UHFFFAOYSA-N 0.000 claims 1
- SSYSQHUWGQTOJV-UHFFFAOYSA-N n-[(4-methylphenyl)methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1CNC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 SSYSQHUWGQTOJV-UHFFFAOYSA-N 0.000 claims 1
- ORRVRGHOSLMGBL-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCCC=3C(=CC=CC=3)Cl)N=CN=C2CC1 ORRVRGHOSLMGBL-UHFFFAOYSA-N 0.000 claims 1
- GBQJHHKPJDWIBU-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCCC=3C=CC(Cl)=CC=3)N=CN=C2CC1 GBQJHHKPJDWIBU-UHFFFAOYSA-N 0.000 claims 1
- SVERNLBOIJHNMU-UHFFFAOYSA-N n-[2-(4-methylphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical class C1=CC(C)=CC=C1CCNC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 SVERNLBOIJHNMU-UHFFFAOYSA-N 0.000 claims 1
- QGRXNGVPOGCLCO-UHFFFAOYSA-N n-[[2-(difluoromethoxy)phenyl]methyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NCC=3C(=CC=CC=3)OC(F)F)N=CN=C2CC1 QGRXNGVPOGCLCO-UHFFFAOYSA-N 0.000 claims 1
- 201000009985 neuronitis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000003254 palate Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 claims 1
- 208000019629 polyneuritis Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000036273 reactive airway disease Diseases 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000003491 tear gas Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67776005P | 2005-05-04 | 2005-05-04 | |
| US60/677,760 | 2005-05-04 | ||
| PCT/US2006/017614 WO2006119504A2 (en) | 2005-05-04 | 2006-05-04 | Fused heterocyclic compounds, and compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012132675A Division JP5722280B2 (ja) | 2005-05-04 | 2012-06-12 | 縮合複素環式化合物、並びにそれらの組成物及び使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008546639A JP2008546639A (ja) | 2008-12-25 |
| JP2008546639A5 true JP2008546639A5 (https=) | 2009-06-25 |
| JP5198256B2 JP5198256B2 (ja) | 2013-05-15 |
Family
ID=37308747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510301A Active JP5198256B2 (ja) | 2005-05-04 | 2006-05-04 | 縮合複素環式化合物、並びにそれらの組成物及び使用 |
| JP2012132675A Active JP5722280B2 (ja) | 2005-05-04 | 2012-06-12 | 縮合複素環式化合物、並びにそれらの組成物及び使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012132675A Active JP5722280B2 (ja) | 2005-05-04 | 2012-06-12 | 縮合複素環式化合物、並びにそれらの組成物及び使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7745451B2 (https=) |
| EP (1) | EP1885369B1 (https=) |
| JP (2) | JP5198256B2 (https=) |
| CA (1) | CA2606760C (https=) |
| ES (1) | ES2552804T3 (https=) |
| MX (1) | MX2007013595A (https=) |
| WO (1) | WO2006119504A2 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007013595A (es) * | 2005-05-04 | 2008-01-24 | Renovis Inc | Compuestos heterociclicos fusionados y composiciones y usos de estos. |
| CA2682162C (en) * | 2007-04-02 | 2016-05-10 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| JP5498374B2 (ja) * | 2007-04-17 | 2014-05-21 | エボテック・アーゲー | ２−シアノフェニル縮合複素環式化合物および組成物、ならびにその使用 |
| CA2703909A1 (en) | 2007-10-31 | 2009-05-07 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| AU2008319309B2 (en) | 2007-10-31 | 2012-09-06 | Merck Sharp & Dohme Llc | P2X3 receptor antagonists for treatment of pain |
| ES2475206T3 (es) | 2008-02-01 | 2014-07-10 | Takeda Pharmaceutical Company Limited | Derivados de oxima como inhibidores de HSP90 |
| MX2010009561A (es) | 2008-02-29 | 2010-09-24 | Renovis Inc | Compuestos amida, composiciones y usos de los mismos. |
| ES2534199T3 (es) | 2008-10-31 | 2015-04-20 | Merck Sharp & Dohme Corp. | Antagonistas del receptor P2X3 para el tratamiento del dolor |
| AU2012202178B2 (en) * | 2008-12-19 | 2012-11-01 | Amgen Inc. | Method for the preparation of 1-acetyl-6-amino-3, 3-dimethyl-2, 3 -dihydroindole |
| MX2011006564A (es) * | 2008-12-19 | 2011-09-26 | Amgen Inc | Procedimiento mejorado para la preparacion de 1-acetil-6-amino-3,3-dimetil-2,3-dihidroindol. |
| MX2011008362A (es) | 2009-02-13 | 2011-08-24 | Shionogi & Co | Derivado novedoso de triazina y composicion farmaceutica que comprende el mismo. |
| AU2010229144B2 (en) | 2009-03-23 | 2012-07-12 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| US8946231B2 (en) | 2009-03-23 | 2015-02-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| WO2010111058A1 (en) | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| DK2604595T3 (en) | 2010-08-10 | 2016-05-23 | Shionogi & Co | TRIAZINE DERIVATIVES AND PHARMACEUTICAL RELATIONSHIP CONTAINING THIS AND PROVIDING ANALGETIC ACTIVITY |
| EP2604260B1 (en) | 2010-08-10 | 2017-05-10 | Shionogi&Co., Ltd. | Novel heterocyclic derivatives and pharmaceutical composition containing same |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| DK2790705T3 (en) | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| FR2984323B1 (fr) * | 2011-12-16 | 2019-08-30 | L'oreal | Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines, composition tinctoriale en comprenant, procedes et utilisations |
| FR2984318B1 (fr) | 2011-12-16 | 2014-06-27 | Oreal | Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines cationiques, composition tinctoriale en comprenant, procedes et utilisations |
| WO2013118855A1 (ja) | 2012-02-09 | 2013-08-15 | 塩野義製薬株式会社 | 複素環および炭素環誘導体 |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| UA112897C2 (uk) | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| TWI499591B (zh) * | 2013-01-11 | 2015-09-11 | Lilly Co Eli | 雙環嘧啶化合物 |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| HRP20201384T1 (hr) | 2014-01-01 | 2020-11-27 | Medivation Technologies Llc | Spojevi i postupci njihove upotrebe |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10183937B2 (en) | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| HUE058009T2 (hu) | 2014-12-09 | 2022-06-28 | Bayer Ag | 1,3-Tiazol-2-il szubsztituált benzamid-származékok |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107597107A (zh) * | 2017-08-30 | 2018-01-19 | 重庆中邦科技有限公司 | 一种2,3‑二氯吡啶生产用催化剂及其制备方法 |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| CA3115939A1 (en) * | 2018-10-10 | 2020-04-16 | Bellus Health Cough Inc. | Treatment of pruritus with p2x3 antagonists |
| AU2020228760A1 (en) | 2019-02-25 | 2021-09-23 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment with P2X3 modulators |
| CN113727758A (zh) * | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN110256420B (zh) * | 2019-05-07 | 2020-04-28 | 江西中医药大学 | 四氢吡啶并嘧啶衍生物及其制备方法和用途 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202128688A (zh) | 2019-11-08 | 2021-08-01 | 美商銳新醫藥公司 | 雙環雜芳基化合物及其用途 |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN116194446A (zh) * | 2020-08-06 | 2023-05-30 | 北京泰德制药股份有限公司 | Sos1抑制剂、包含其的药物组合物及其用途 |
| JP2023550830A (ja) * | 2020-11-27 | 2023-12-05 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐ２ｘ３阻害剤としての（アザ）キノリン４－アミン誘導体 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| CN115626922A (zh) * | 2021-04-29 | 2023-01-20 | 苏州恩华生物医药科技有限公司 | 5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-醇衍生物及其应用 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1197466B (de) * | 1962-03-22 | 1965-07-29 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen |
| US3424761A (en) | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
| US3424760A (en) | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
| DE2502588A1 (de) | 1975-01-23 | 1976-07-29 | Troponwerke Dinklage & Co | Basisch substituierte derivate des 7-amino-2-chinolons, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| JPH04224580A (ja) | 1990-12-25 | 1992-08-13 | Nippon Soda Co Ltd | ピリミジン誘導体、その製造方法及び農園芸用殺菌剤 |
| ATE306481T1 (de) | 1999-05-12 | 2005-10-15 | Ortho Mcneil Pharm Inc | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen |
| EP1230225A2 (en) | 1999-11-01 | 2002-08-14 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
| CN100335479C (zh) | 1999-12-17 | 2007-09-05 | 希龙公司 | 糖元合成酶激酶3的双环抑制剂 |
| US7087589B2 (en) | 2000-01-14 | 2006-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methanocarba cycloakyl nucleoside analogues |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| JP2004525071A (ja) | 2000-07-20 | 2004-08-19 | ニューロジェン コーポレイション | カプサイシン受容体リガンド |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| NZ526472A (en) | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| CA2432578C (en) * | 2001-01-02 | 2008-04-01 | F. Hoffmann-La Roche Ag | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| DE60206363T2 (de) * | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US7105667B2 (en) * | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| JP4469179B2 (ja) | 2002-01-23 | 2010-05-26 | バイエル ファーマセチカル コーポレーション | Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体 |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| US20060239999A1 (en) * | 2002-08-22 | 2006-10-26 | Mayumi Saki | Preventive and/or therapeutic drugs for asthma |
| CA2496464A1 (en) * | 2002-08-22 | 2004-03-04 | Kyowa Hakko Kogyo Co., Ltd. | Agent for prevention and/or treatment of itching |
| GB0225908D0 (en) | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| WO2004056774A2 (en) | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
| JP2006521398A (ja) | 2003-03-28 | 2006-09-21 | サイオス・インコーポレーテツド | ＴＧＦβの二−環式ピリミジン阻害剤 |
| US7232833B2 (en) * | 2003-03-28 | 2007-06-19 | Novexel | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them |
| WO2004093912A1 (ja) | 2003-04-23 | 2004-11-04 | Kyowa Hakko Kogyo Co. Ltd. | 好中球性炎症疾患の予防および／または治療剤 |
| ZA200601859B (en) * | 2003-08-05 | 2008-03-26 | Vertex Pharma | Condensed pyrimidine compounds as inhibitors of voltagegated ion channels |
| US7390820B2 (en) | 2003-08-25 | 2008-06-24 | Amgen Inc. | Substituted quinolinone derivatives and methods of use |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| JP2005162673A (ja) | 2003-12-03 | 2005-06-23 | Kyowa Hakko Kogyo Co Ltd | 二環性ピリミジン誘導体 |
| WO2006035061A1 (en) | 2004-09-30 | 2006-04-06 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting bi-cyclic pyrimidines |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| MX2007013595A (es) * | 2005-05-04 | 2008-01-24 | Renovis Inc | Compuestos heterociclicos fusionados y composiciones y usos de estos. |
| JP5400388B2 (ja) | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼインヒビターおよびその利用 |
| WO2013033981A1 (zh) * | 2011-09-06 | 2013-03-14 | 江苏先声药物研究有限公司 | 一类2,7-萘啶衍生物及其制备方法和应用 |
-
2006
- 2006-05-04 MX MX2007013595A patent/MX2007013595A/es active IP Right Grant
- 2006-05-04 WO PCT/US2006/017614 patent/WO2006119504A2/en not_active Ceased
- 2006-05-04 US US11/429,026 patent/US7745451B2/en active Active
- 2006-05-04 ES ES06770066.6T patent/ES2552804T3/es active Active
- 2006-05-04 JP JP2008510301A patent/JP5198256B2/ja active Active
- 2006-05-04 CA CA2606760A patent/CA2606760C/en active Active
- 2006-05-04 EP EP06770066.6A patent/EP1885369B1/en active Active
-
2010
- 2010-03-01 US US12/660,588 patent/US8859545B2/en active Active
-
2012
- 2012-06-12 JP JP2012132675A patent/JP5722280B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008546639A5 (https=) | ||
| JP2007509043A5 (https=) | ||
| JP2010524930A5 (https=) | ||
| US7868001B2 (en) | Cytokine inhibitors | |
| JP4115518B2 (ja) | 新規３，５−ジオキソ−（２ｈ，４ｈ）−１，２，４−トリアジン誘導体、それらの調製および薬剤としての使用 | |
| JP5198256B2 (ja) | 縮合複素環式化合物、並びにそれらの組成物及び使用 | |
| JP2012502986A5 (https=) | ||
| JP2011514894A5 (https=) | ||
| CN101899011B (zh) | 氨基二硫代甲酸酯类化合物、其制备方法和应用 | |
| JP2010523562A5 (https=) | ||
| EP1796673A2 (en) | Novel pyrimidine compounds, process for their preparation and compositions containing them | |
| CN109111426B (zh) | 一类稠合双环杂芳基或芳基化合物，及其用途 | |
| JPS59130276A (ja) | グアニジン誘導体 | |
| JP2007536374A (ja) | ヒスタミンｈ３受容体リガンドとして有用なテトラヒドロナフチリヂン誘導体 | |
| BRPI1014956B1 (pt) | agentes anti-inflamatórios | |
| PT2010536E (pt) | Imidazo[1,2-b]piridazinas, seus processos de preparação e seu uso como ligantes de receptores gaba | |
| CN105503837A (zh) | 具有Aurora激酶抑制活性的取代喹唑啉类衍生物及其应用 | |
| JP2011503072A5 (https=) | ||
| US6288061B1 (en) | Imidazole derivatives | |
| CN103739550B (zh) | 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用 | |
| CN107739368B (zh) | N-取代-5-（（4-取代嘧啶-2-基）氨基）吲哚类衍生物及其制备方法和用途 | |
| PL151696B1 (en) | Method of obtaining derivatives of quinolone | |
| JP2011509296A5 (https=) | ||
| CN102206222B (zh) | 一种双脂肪氨基取代吲哚喹啉衍生物及其制备方法和制备抗肿瘤药物中的应用 | |
| BRPI0611537A2 (pt) | (3,4-diidro-quinazolin-2-il) -(2-arilóxi-etil)-aminas tendo uma atividade sobre o receptor de 5-ht |